ATE466029T1 - Verfahren zur modulation der proliferation von schilddrüsenkrebszellen - Google Patents

Verfahren zur modulation der proliferation von schilddrüsenkrebszellen

Info

Publication number
ATE466029T1
ATE466029T1 AT07006462T AT07006462T ATE466029T1 AT E466029 T1 ATE466029 T1 AT E466029T1 AT 07006462 T AT07006462 T AT 07006462T AT 07006462 T AT07006462 T AT 07006462T AT E466029 T1 ATE466029 T1 AT E466029T1
Authority
AT
Austria
Prior art keywords
cys
cancer cell
cell proliferation
thyroid cancer
cyclo
Prior art date
Application number
AT07006462T
Other languages
English (en)
Inventor
Uberti Ettore Ciro Degli
Michael Dewitt Culler
Maria Chiara Zatelli
David H Coy
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of ATE466029T1 publication Critical patent/ATE466029T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07006462T 2001-03-06 2002-03-06 Verfahren zur modulation der proliferation von schilddrüsenkrebszellen ATE466029T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27369901P 2001-03-06 2001-03-06

Publications (1)

Publication Number Publication Date
ATE466029T1 true ATE466029T1 (de) 2010-05-15

Family

ID=23045039

Family Applications (3)

Application Number Title Priority Date Filing Date
AT02725077T ATE362489T1 (de) 2001-03-06 2002-03-06 Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen
AT07006462T ATE466029T1 (de) 2001-03-06 2002-03-06 Verfahren zur modulation der proliferation von schilddrüsenkrebszellen
AT07006463T ATE430162T1 (de) 2001-03-06 2002-03-06 Verfahren zur modulation der proliferation von schilddrüsenkrebszellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02725077T ATE362489T1 (de) 2001-03-06 2002-03-06 Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07006463T ATE430162T1 (de) 2001-03-06 2002-03-06 Verfahren zur modulation der proliferation von schilddrüsenkrebszellen

Country Status (10)

Country Link
US (3) US20050124549A1 (de)
EP (3) EP1813625B1 (de)
JP (2) JP4294959B2 (de)
AT (3) ATE362489T1 (de)
CA (2) CA2743731C (de)
DE (3) DE60232203D1 (de)
ES (3) ES2284859T3 (de)
NO (1) NO20033881L (de)
RU (3) RU2352578C2 (de)
WO (1) WO2002070555A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262229B1 (en) * 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
RU2352578C2 (ru) * 2001-03-06 2009-04-20 Иль Консорцио Феррара Ричерке Способ модуляции пролиферации клеток медуллярной карциномы щитовидной железы
DK1372688T3 (da) * 2001-03-08 2008-08-25 Univ Tulane Somatostatin-antagonister
EP1522311A1 (de) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds
WO2007112045A2 (en) 2006-03-23 2007-10-04 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of somatostatin agonists to treat medullary thyroid carcinoma
EP2835136A1 (de) 2013-08-07 2015-02-11 PregLem S.A. Somatostatin Receptor Modulator zur Unfruchtbarkeitsbehandlung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
EP1288224B1 (de) 1993-08-09 2008-06-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Derivate therapeutischer Peptide
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
PT979098E (pt) 1997-05-01 2003-07-31 Cedars Sinai Medical Center Metodo para o tratamento da hiperprolactinemia e de prolactinomas
US6180082B1 (en) * 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
JP2001513114A (ja) 1997-11-24 2001-08-28 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ 放射性同位元素標識した化合物の組織への蓄積を促進するための方法
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
IL140837A0 (en) 1998-07-30 2002-02-10 Sod Conseils Rech Applic Method of using lanreotide, a somatostatin analogue
CN1367792A (zh) * 1999-06-25 2002-09-04 研究及应用科学协会股份有限公司 促生长素抑制素激动剂
RU2352578C2 (ru) * 2001-03-06 2009-04-20 Иль Консорцио Феррара Ричерке Способ модуляции пролиферации клеток медуллярной карциномы щитовидной железы

Also Published As

Publication number Publication date
RU2275934C2 (ru) 2006-05-10
EP1390406B1 (de) 2007-05-16
RU2007111864A (ru) 2008-10-10
DE60236225D1 (de) 2010-06-10
DE60220157D1 (de) 2007-06-28
EP1813625B1 (de) 2009-04-29
ATE430162T1 (de) 2009-05-15
EP1390406A2 (de) 2004-02-25
CA2743731A1 (en) 2002-09-12
ES2284859T3 (es) 2007-11-16
CA2440214A1 (en) 2002-09-12
ES2328077T3 (es) 2009-11-06
ATE362489T1 (de) 2007-06-15
DE60220157T2 (de) 2008-01-17
EP1813625A1 (de) 2007-08-01
EP1897889A2 (de) 2008-03-12
RU2003129515A (ru) 2005-03-27
US20070259811A1 (en) 2007-11-08
EP1897889A3 (de) 2008-03-26
RU2317824C2 (ru) 2008-02-27
US20050124549A1 (en) 2005-06-09
WO2002070555A2 (en) 2002-09-12
RU2352578C2 (ru) 2009-04-20
EP1897889B1 (de) 2010-04-28
NO20033881D0 (no) 2003-09-02
CA2440214C (en) 2012-05-22
JP4294959B2 (ja) 2009-07-15
JP4828438B2 (ja) 2011-11-30
US20110183416A1 (en) 2011-07-28
JP2007145854A (ja) 2007-06-14
RU2005132456A (ru) 2007-04-27
NO20033881L (no) 2003-10-10
US9220760B2 (en) 2015-12-29
JP2005506289A (ja) 2005-03-03
DE60232203D1 (de) 2009-06-10
WO2002070555A3 (en) 2003-12-04
CA2743731C (en) 2014-05-06
ES2345280T3 (es) 2010-09-20

Similar Documents

Publication Publication Date Title
ATE430563T1 (de) Cyano-substituierte oleanolsäure als inhibitor der no-produktion
DE69128516D1 (de) Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer
BR9804214A (pt) Compostos.
ATE495736T1 (de) Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel
EA200201071A1 (ru) Циклопентилзамещенные производные глутарамида в качестве ингибиторов нейтральной эндопептидазы
ATE220317T1 (de) Verwendung von betainen als antitranspirantien
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
EA199800109A1 (ru) Производные азетидинона для лечения атеросклероза
GB9715030D0 (en) Metalloproteinase inhibitors
ATE430162T1 (de) Verfahren zur modulation der proliferation von schilddrüsenkrebszellen
ATE191317T1 (de) Verwendung von beta-aminopropionsäure-derivaten als fungizide
DE59307409D1 (de) Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
DK1272457T3 (da) Forbindelser til modulation af celleproliferation
ATE211719T1 (de) Korrosionsinhibitoren enthaltender injektionszement
ES2179254T3 (es) 1-poliarilpirazoles plaguicidas.
DE60125378D1 (de) Verfahren zur herstellung von 2-aminomethyl-halogen-pyridinen
ATE339475T1 (de) Verfahren zur hydrophilierung von fluoreszierenden markierstoffen
DE69431824D1 (de) Verfahren zur Herstellung von Schwefelhaltigen Imidazolderivaten und erhaltene Zwischenprodukte
ATE385232T1 (de) Verfahren zur herstellung von 3, 3', 6, 6'- tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'- tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
IN190321B (de)
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
EA199800242A1 (ru) Амиды карбамоилкарбоновой кислоты
PT1156999E (pt) Metodo para a preparacao de um beta-aminoester quiral
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
ATE135352T1 (de) 3-keto-hmg-coa reduktase-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties